» Articles » PMID: 22286307

Preexisting Influenza-specific CD4+ T Cells Correlate with Disease Protection Against Influenza Challenge in Humans

Abstract

Protective immunity against influenza virus infection is mediated by neutralizing antibodies, but the precise role of T cells in human influenza immunity is uncertain. We conducted influenza infection studies in healthy volunteers with no detectable antibodies to the challenge viruses H3N2 or H1N1. We mapped T cell responses to influenza before and during infection. We found a large increase in influenza-specific T cell responses by day 7, when virus was completely cleared from nasal samples and serum antibodies were still undetectable. Preexisting CD4+, but not CD8+, T cells responding to influenza internal proteins were associated with lower virus shedding and less severe illness. These CD4+ cells also responded to pandemic H1N1 (A/CA/07/2009) peptides and showed evidence of cytotoxic activity. These cells are an important statistical correlate of homotypic and heterotypic response and may limit severity of influenza infection by new strains in the absence of specific antibody responses. Our results provide information that may aid the design of future vaccines against emerging influenza strains.

Citing Articles

The Potential for Twice-Annual Influenza Vaccination to Reduce Disease Burden.

Zhong S, Thompson M, Cowling B Influenza Other Respir Viruses. 2025; 19(3):e70052.

PMID: 40045876 PMC: 11883281. DOI: 10.1111/irv.70052.


Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses.

Zhao Y, Guo S, Liu J, Wang Y, Wang B, Peng C Front Immunol. 2025; 16:1519866.

PMID: 39958330 PMC: 11827429. DOI: 10.3389/fimmu.2025.1519866.


T cell-mediated protection in absence of virus neutralizing antibodies.

Alpizar Y, Dallmeier K Nat Microbiol. 2025; 10(2):277-278.

PMID: 39849084 DOI: 10.1038/s41564-024-01921-5.


Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults.

Jacobs B, Leroux-Roels I, Bruhwyler J, Groth N, Waerlop G, Janssens Y Vaccines (Basel). 2025; 12(12.

PMID: 39772052 PMC: 11728545. DOI: 10.3390/vaccines12121391.


Preexisting vaccine-primed heterosubtypic T cell immunity protects the maternal-fetal unit from adverse influenza outcomes in mice.

Flores Malavet V, Dhume K, Satchmei A, Arvelo A, Beaird A, Annamalai S J Clin Invest. 2025; 135(1).

PMID: 39744951 PMC: 11684801. DOI: 10.1172/JCI179230.


References
1.
Both G, Sleigh M, Cox N, Kendal A . Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol. 1983; 48(1):52-60. PMC: 255321. DOI: 10.1128/JVI.48.1.52-60.1983. View

2.
Yang O, Kalams S, Rosenzweig M, Trocha A, Jones N, Koziel M . Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol. 1996; 70(9):5799-806. PMC: 190594. DOI: 10.1128/JVI.70.9.5799-5806.1996. View

3.
Appay V, Zaunders J, Papagno L, Sutton J, Jaramillo A, Waters A . Characterization of CD4(+) CTLs ex vivo. J Immunol. 2002; 168(11):5954-8. DOI: 10.4049/jimmunol.168.11.5954. View

4.
Roti M, Yang J, Berger D, Huston L, James E, Kwok W . Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol. 2008; 180(3):1758-68. PMC: 3373268. DOI: 10.4049/jimmunol.180.3.1758. View

5.
Treanor J . Influenza vaccine--outmaneuvering antigenic shift and drift. N Engl J Med. 2004; 350(3):218-20. DOI: 10.1056/NEJMp038238. View